IceCure Medical Ltd.(ICCM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ICCM IceCure Medical Ltd.

Trading 01-16 14:02:41 EST

0.6821

-0.0016

-0.23%

High0.7099	Low0.6606	Vol159.87K
Open0.6837	D1 Closing0.6837	Amplitude7.21%
Mkt Cap47.04M	Tradable Cap27.81M	Total Shares68.96M
T/O109.98K	T/O Rate0.39%	Tradable Shares40.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ICCM","market":"US","secType":"STK","nameCN":"IceCure Medical Ltd.","latestPrice":0.6821,"timestamp":1768589941660,"preClose":0.6837,"halted":0,"volume":159871,"delay":0,"floatShares":40777100,"shares":68963210,"eps":-0.257292,"marketStatus":"Trading","change":-0.0016,"latestTime":"01-16 14:02:41 EST","open":0.6837,"high":0.7099,"low":0.6606,"amount":109980.536643,"amplitude":0.072108,"askPrice":0.6897,"askSize":500,"bidPrice":0.6821,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.257292,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768597200000},"marketStatusCode":2,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":0.6837,"preHourTrading":{"tag":"盘前","latestPrice":0.6839,"preClose":0.6837,"latestTime":"09:15 EST","volume":115,"amount":78.64699925,"timestamp":1768572922925},"postHourTrading":{"tag":"盘后","latestPrice":0.6839,"preClose":0.6837,"latestTime":"19:30 EST","volume":2980,"amount":2038.71329,"timestamp":1768523441333},"volumeRatio":0.689154},"requestUrl":"/m/hq/s/ICCM","defaultTab":"news","newsList":[{"id":"2602431535","title":"IceCure Medical sees FY25 ProSense sales $3.4M","url":"https://stock-news.laohu8.com/highlight/detail?id=2602431535","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602431535?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:51","pubTimestamp":1768225893,"startTime":"0","endTime":"0","summary":"A letter from CEO Eyal Shamir to shareholders stated, in part, “2025 was a pivotal year for IceCure – we were granted the U.S. Food and Drug Admini...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/icecure-medical-sees-fy25-prosense-sales-3-4m-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/icecure-medical-sees-fy25-prosense-sales-3-4m-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ICCM"],"gpt_icon":0},{"id":"2602854813","title":"IceCure Medical Reports Record 2025 ProSense Sales and Increased U.S. Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2602854813","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602854813?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:31","pubTimestamp":1768224661,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. reported record sales of its ProSense cryoablation system, reaching approximately $3.4 million for the year ended December 31, 2025. The company attributed the growth to increased demand in the U.S. following FDA marketing authorization of ProSense for the local treatment of low-risk breast cancer, as well as record sales in Europe. As of December 31, 2025, IceCure reported a cash and cash equivalents balance of approximately $8.9 million. The company also noted a record number of peer-reviewed publications and conference presentations covering ProSense’s use in breast, musculoskeletal, and kidney cancers. These preliminary financial results are unaudited and subject to final adjustments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLbdsC5T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2602025983","title":"BRIEF-IceCure Medical Entered Into Amendment To Equity Distribution Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2602025983","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602025983?lang=en_us&edition=fundamental","pubTime":"2026-01-10 06:48","pubTimestamp":1767998909,"startTime":"0","endTime":"0","summary":"BRIEF-IceCure Medical Entered Into Amendment To Equity Distribution AgreementJan 9  - Icecure Medical Ltd ICCM.O:ICECURE MEDICAL LTD: ENTERED INTO AMENDMENT TO EQUITY DISTRIBUTION AGREEMENT- SEC FILINGICECURE MEDICAL LTD: AMENDMENT TO EXTEND AGREEMENT’S TERMINATION DATE TO MARCH 13, 2026 - SEC FILINGSource text: [ID:n0001213900-26-002943]Further company coverage: ICCM.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA1PC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2602930459","title":"IceCure Medical Extends Equity Distribution Agreement with Maxim Group to March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602930459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602930459?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:58","pubTimestamp":1767995905,"startTime":"0","endTime":"0","summary":"An update from Icecure Medical ( ($ICCM) ) is now available. On January 8, 2026, IceCure Medical Ltd. signed a first amendment to its equity distri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icecure-medical-extends-equity-distribution-agreement-with-maxim-group-to-march-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icecure-medical-extends-equity-distribution-agreement-with-maxim-group-to-march-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ICCM","EQD","BK4082"],"gpt_icon":0},{"id":"2602264301","title":"Icecure Medical Ltd: Entered Into Amendment to Equity Distribution Agreement- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602264301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602264301?lang=en_us&edition=fundamental","pubTime":"2026-01-10 05:43","pubTimestamp":1767995021,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA1PC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2602151313","title":"IceCure Medical Shareholders Approve Amended Articles of Association at January 7 Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2602151313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602151313?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:28","pubTimestamp":1767907697,"startTime":"0","endTime":"0","summary":"Icecure Medical ( ($ICCM) ) just unveiled an announcement. On January 7, 2026, IceCure Medical held a Special General Meeting of Shareholders in wh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icecure-medical-shareholders-approve-amended-articles-of-association-at-january-7-special-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icecure-medical-shareholders-approve-amended-articles-of-association-at-january-7-special-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2601361756","title":"When Can We Expect A Profit From IceCure Medical Ltd (NASDAQ:ICCM)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2601361756","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601361756?lang=en_us&edition=fundamental","pubTime":"2026-01-08 18:51","pubTimestamp":1767869477,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd ( NASDAQ:ICCM ) is possibly approaching a major achievement in its business, so we would like to...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-iccm/icecure-medical/news/when-can-we-expect-a-profit-from-icecure-medical-ltd-nasdaqi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-iccm/icecure-medical/news/when-can-we-expect-a-profit-from-icecure-medical-ltd-nasdaqi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TQQQ","SQQQ",".IXIC","QID","NQmain","PSQ","TSYW.SI","QLD","USAW.SI","BK4082","USJW.SI","NVIW.SI","MNQmain","ICCM"],"gpt_icon":1},{"id":"2592181539","title":"IceCure Medical Expects Record Fourth Quarter North American Sales Following FDA Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2592181539","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592181539?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:30","pubTimestamp":1765978259,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. announced that it expects to report record fourth quarter sales in North America, driven by the recent FDA clearance of its ProSense cryoablation system for the treatment of low-risk breast cancer in women aged 70 and above. The company reported that ProSense systems are being sold and installed at new locations across North America, including several highly regarded medical institutions in the United States. IceCure stated that the FDA's marketing authorization has acted as a major catalyst for growth in its sales pipeline. The company plans to release preliminary top-line revenue results in January 2026, followed by its full annual report on Form 20-F in April 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5q1mKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2590587050","title":"IceCure Medical Showcases ProSense Cryoablation Data at RSNA 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590587050","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590587050?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:30","pubTimestamp":1765373430,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. participated in the Radiological Society of North America's  Annual Meeting, held from November 30 to December 4, 2025, in Chicago, Illinois. At this prestigious event, four independent studies featuring IceCure's ProSense cryoablation technology for breast cancer treatment were presented. The studies, conducted by ProSense users, highlighted the effectiveness and growing adoption of the company's minimally-invasive cryoablation system as an alternative to surgical tumor removal. The event attracted around 50,000 attendees from 160 countries, providing a global platform for showcasing advancements in radiology and cancer care.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the origina","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL7kFzb9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2589189061","title":"IceCure Medical Receives Patent Allowance in China for Next-Generation Cryogen Flow Control Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189061","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589189061?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:30","pubTimestamp":1764941435,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. announced it has received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled \"Cryogen Flow Control,\" related to its next-generation XSense cryoablation system and probes. The patent addresses precise temperature control during cryoablation procedures by using sensor data to regulate the flow of cryogens, optimizing treatment efficacy and tissue safety. This development is part of the company's expanding intellectual property portfolio in cryoablation technology, which includes 55 patents granted and allowed globally. The invention may also facilitate additional functionalities such as navigation and mapping support within the body. Patent applications for this invention are currently pending in the European Union, the U.S., and other major markets, while it has already been granted in Japan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL2CT3xr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2584901736","title":"IceCure Medical Reports Q3 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584901736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584901736?lang=en_us&edition=fundamental","pubTime":"2025-11-20 12:02","pubTimestamp":1763611376,"startTime":"0","endTime":"0","summary":"Icecure Medical Ltd. ( ($ICCM) ) has released its Q3 earnings. Here is a breakdown of the information Icecure Medical Ltd. presented to its investo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icecure-medical-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icecure-medical-reports-q3-2025-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2584977854","title":"IceCure Medical’s Earnings Call Highlights Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2584977854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584977854?lang=en_us&edition=fundamental","pubTime":"2025-11-20 08:09","pubTimestamp":1763597354,"startTime":"0","endTime":"0","summary":"Icecure Medical Ltd. (($ICCM)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call from IceCure Me...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icecure-medicals-earnings-call-highlights-growth-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icecure-medicals-earnings-call-highlights-growth-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ICCM"],"gpt_icon":0},{"id":"2584222499","title":"IceCure Medical Announces Receipt Of Nasdaq Minimum Bid Price Notification","url":"https://stock-news.laohu8.com/highlight/detail?id=2584222499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584222499?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:48","pubTimestamp":1763574526,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - Icecure Medical Ltd ::*ICECURE MEDICAL ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID PRICE NOTIFICATION  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 14-NOV-202521:30:00.027 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD7LPTd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2584494208","title":"BRIEF-Icecure Reports Financial & Operational Results For The Nine Months Ended September 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584494208","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584494208?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:22","pubTimestamp":1763562132,"startTime":"0","endTime":"0","summary":"BRIEF-Icecure Reports Financial & Operational Results For The Nine Months Ended September 30, 2025Icecure Medical Ltd ICCM.O:ICECURE REPORTS FINANCIAL & OPERATIONAL RESULTS FOR THE NINE MONTHS ENDED S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUAC1BQ5W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2584094259","title":"Icecure Medical Q3 EPS $0.06 Beats $(0.05) Estimate, Sales $850.000K Beat $714.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2584094259","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584094259?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:08","pubTimestamp":1763561318,"startTime":"0","endTime":"0","summary":"Icecure Medical (NASDAQ:ICCM) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.05) by 220 percent. This is a 175 percent increase over losses of $(0.08) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48948412/icecure-medical-q3-eps-0-06-beats-0-05-estimate-sales-850-000k-beat-714-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2584317942","title":"IceCure Medical reports nine-month financial results through September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584317942","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584317942?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:05","pubTimestamp":1763561142,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. reported financial results for the nine months ended September 30, 2025. Research and development expenses were $5.1 million, down from $5.4 million in the same period in 2024, mainly due to reduced service provider and clinical trial costs following the conclusion of the ICE3 study in 2024. Sales and marketing expenses declined to $3.1 million from $4.0 million a year earlier, primarily reflecting a reduction in service providers and consultants. The company noted a 9% decrease in revenue from sales of ProSense systems and disposable probes in Japan. IceCure highlighted momentum in the U.S. market and global interest after receiving FDA marketing authorization for local cryoablation treatment of low-risk breast cancer, with demand for ProSense systems expected to accelerate in 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL6z161T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","ICCM"],"gpt_icon":0},{"id":"2584944461","title":"IceCure Medical Wins FDA Approval for ProSense Cryoablation System for Low-Risk Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944461","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944461?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:54","pubTimestamp":1763560493,"startTime":"0","endTime":"0","summary":"IceCure Medical Ltd. has received significant regulatory approvals for its cryoablation technologies. The company announced that its ProSense system has been granted FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and above and patients not suitable for surgery, marking a major milestone that opens the U.S. market for its minimally invasive technology. In addition, ProSense and its cryoprobes are now cleared for commercial sale in Switzerland for use in the treatment of malignant or benign tissue in the breast, lung, liver, kidney, and musculoskeletal system, including palliative care. Furthermore, Israel has granted regulatory approval for IceCure's next-generation XSense Cryoablation System for breast cancer and other indications, while XSense and its cryoprobes have received a Notice of Allowance for patents in both the U.S. and Japan, strengthening the company's intellectual property portfolio.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL6yRvDb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2584944465","title":"Icecure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584944465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584944465?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:54","pubTimestamp":1763560471,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUAC1BQ5W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2584473944","title":"Icecure Medical: Demand for Prosense Systems Expected to Accelerate in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2584473944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584473944?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:54","pubTimestamp":1763560471,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUAC1BQ5W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ICCM","BK4082"],"gpt_icon":0},{"id":"2584588929","title":"BRIEF-Icecure's Prosense® Cryoablation System Receives Regulatory Approval In Switzerland For Indications Including Breast, Lung, Liver, And Kidney Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2584588929","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584588929?lang=en_us&edition=fundamental","pubTime":"2025-11-18 21:38","pubTimestamp":1763473110,"startTime":"0","endTime":"0","summary":"BRIEF-Icecure's Prosense Cryoablation System Receives Regulatory Approval In Switzerland For Indications Including Breast, Lung, Liver, And Kidney CancerIcecure Medical Ltd ICCM.O:ICECURE'S PROSENSE C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nFWN3WU0XS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ICCM","BK4082"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.icecure-medical.com","stockEarnings":[{"period":"1week","weight":-0.0261},{"period":"1month","weight":0.0927},{"period":"3month","weight":-0.1614},{"period":"6month","weight":-0.3297},{"period":"1year","weight":-0.4441},{"period":"ytd","weight":0.1206}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030529},{"month":2,"riseRate":0.5,"avgChangeRate":-0.01707},{"month":3,"riseRate":0.5,"avgChangeRate":-0.050521},{"month":4,"riseRate":0.5,"avgChangeRate":0.014871},{"month":5,"riseRate":0,"avgChangeRate":-0.140983},{"month":6,"riseRate":0.25,"avgChangeRate":-0.086655},{"month":7,"riseRate":0.75,"avgChangeRate":0.017122},{"month":8,"riseRate":0.25,"avgChangeRate":-0.047246},{"month":9,"riseRate":0,"avgChangeRate":-0.204904},{"month":10,"riseRate":0.4,"avgChangeRate":0.0455},{"month":11,"riseRate":0.6,"avgChangeRate":-0.016804},{"month":12,"riseRate":0.4,"avgChangeRate":0.06553}],"exchange":"NASDAQ","name":"IceCure Medical Ltd.","nameEN":"IceCure Medical Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IceCure Medical Ltd.(ICCM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IceCure Medical Ltd.(ICCM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IceCure Medical Ltd.,ICCM,IceCure Medical Ltd.股票,IceCure Medical Ltd.股票老虎,IceCure Medical Ltd.股票老虎国际,IceCure Medical Ltd.行情,IceCure Medical Ltd.股票行情,IceCure Medical Ltd.股价,IceCure Medical Ltd.股市,IceCure Medical Ltd.股票价格,IceCure Medical Ltd.股票交易,IceCure Medical Ltd.股票购买,IceCure Medical Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IceCure Medical Ltd.(ICCM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IceCure Medical Ltd.(ICCM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}